Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 18/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021605 | 0.88 | ACLY (0.66) | ACLY | |
| SCHEMBL22004211 | 0.86 | ACLY (0.64) | ACLY | |
| SCHEMBL14433929 | 0.83 | ACLY (0.72) | ACLYHPGDTSHRMCL1CCR2 | |
| SCHEMBL22004216 | 0.80 | ACLY (0.55) | ACLYHPGDTSHRMCL1CCR2 | |
| SCHEMBL22004212 | 0.79 | ACLY (0.67) | ACLY | |
| SCHEMBL22005135 | 0.79 | HSP90AA1 (0.54) | ACLYHPGDTSHRMCL1 | |
| SCHEMBL11650550 | 0.78 | ACLY (0.67) | ACLYMCL1CCR2 | |
| SCHEMBL22021608 | 0.77 | ACLY (0.63) | ACLYMCL1 | |
| SCHEMBL21999962 | 0.77 | ACLY (1.00) | ACLY | |
| SCHEMBL11652003 | 0.75 | ACLY (0.63) | ACLYCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885HPGD 1212/4885TSHR 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.